Every material Form 8-K cbdMD, Inc. has filed with the SEC since May 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 30, 2026, cbdMD completed its acquisition of operating assets from Twinlab Consolidated Holdings through a court-approved creditor sale. The company assumed $1.75 million of senior secured debt owed to Akretive Holdings, LLC, and issued that creditor 2,229,805 common shares, equal to 19.9% of shares outstanding at signing, with 132,730 more shares planned subject to shareholder approval. The deal adds nutritional supplement brands and moves cbdMD beyond hemp products, but it also adds secured debt and share issuance that dilutes existing holders.
Closed October 30, 2026, after a Broward County, Florida court approved the sale as a private sale; the seller was the assignee for the benefit of creditors, Philip J. Von Kahle.
Issued 2,229,805 common shares, valued at $1.00 per share, to Akretive Holdings, LLC, representing 19.9% of shares outstanding at signing.
Assumed a $1,750,000 senior secured note bearing 9% annual interest, maturing two years after the closing date and secured by the acquired assets.
Acquired brands include Twinlab, Reserveage, Metabolife and ResVitale; 132,730 additional shares are subject to shareholder approval within 270 days of closing.
On September 1, 2026, cbdMD agreed to acquire assets of Twinlab through an assignment for the benefit of creditors, subject to court approval. The consideration is assumption of about $1.75 million of debt owed to Akretive Holdings plus 2,229,805 new common shares, equal to 19.9% of outstanding stock, which dilutes existing shareholders. The company also cut the conversion price of its Series B preferred stock from $1.00 to $0.60, effective September 2, 2026.
Consideration: assumption of about $1,750,000 of debt owed to Akretive Holdings, plus 2,229,805 common shares (19.9% of outstanding shares at signing).
Deal runs through an assignment for the benefit of creditors; closing requires a sale order from the ABC Court. The company expects to complete the deal in its first fiscal quarter.
Company states combined unaudited trailing twelve-month revenue to June 2026 of about $30 million, about 40% above cbdMD standalone revenue for the same period; it says this figure is illustrative only.
Series B conversion price cut from $1.00 to $0.60 effective September 2, 2026; 591,207 Series B shares are outstanding.
cbdMD signed a Third Amendment to its Charlotte warehouse lease, which also serves as its executive offices, extending the term 62 months to November 30, 2031, for 40,000 square feet. The company says the amendment reduces annual gross rent expense by approximately $450,000 and net rent expense by approximately $100,000 to $120,000 after sublet rent, which lowers operating costs for shareholders over the extended term.
Lease extended 62 months from October 1, 2026, to November 30, 2031, covering 40,000 square feet at 2101 Westinghouse Boulevard, Charlotte
Monthly base rent reduced to $38,000 for the initial year of the renewal term; base rent abated from October 1, 2026, through November 30, 2026
Annual gross rent expense reduction of approximately $450,000; net reduction of approximately $100,000 to $120,000 after sublet rent
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every cbdMD, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →